AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain

 AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company's presentation at the pain conference EFIC 2023 is now available in its entirety on the company's website. The presentation contains clinical phase II data with the company's leading clinical candidate drug in pain, Painless ACD440, which is being developed with a focus on neuropathic pain.

https://www.biospace.com/article/releases/alzecure-presents-positive-phase-ii-clinical-data-with-acd440-against-neuropathic-pain-at-efic-2023-conference/